

Sex differences

Introduction

The incidence of schizophrenia refers to how many new cases there are per population in a specified time-period. It is different from prevalence, which refers to how many existing cases there are at a particular point in time. Incidence is usually reported as the number of new cases per 100,000 people per year. Alternatively, some studies present the number of new cases that have accumulated over several years against a person-years denominator. This denominator is the sum of individual units of time that the persons in the population are at risk of developing schizophrenia. It takes into account the size of the underlying population sample and its age structure over the duration of observation.

Differences in the incidence of a disorder can provide clues to its possible causes. For example, a population register with information gained from consensus data helps to identify all adults who were born within a certain time-period (an age cohort). Cross linking this information with a mental health register can be used to identify those who received treatment for schizophrenia over specific time-periods. This can provide information regarding the incidence of schizophrenia for each sex.

Method

We have included only systematic reviews with detailed literature search, methodology, and inclusion/exclusion criteria that were published in full text, in English, from the year 2000. Reviews were identified by searching the databases MEDLINE, EMBASE, and PsycINFO. Reviews with pooled data are prioritized for inclusion. Reviews reporting fewer than 50% of items on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([PRISMA](#)¹) checklist have been excluded from the library. The evidence was graded guided by the Grading of Recommendations Assessment, Development and Evaluation ([GRADE](#)) Working Group

approach². The resulting table represents an objective summary of the available evidence, although the conclusions are solely the opinion of staff of NeuRA (Neuroscience Research Australia).

Results

We found three systematic reviews that met our inclusion criteria³⁻⁵.

- Moderate to high quality evidence suggests the incidence rate of schizophrenia is higher in men than in women. This is only apparent in men up until 39 years of age, then the incidence is higher in females after 50 years of age. These results remain after adjusting for year of study, sample size, sampling method (admission or contact), case ascertainment (clinical, systematic or interview), and diagnostic classification system.

Sex differences

SCHIZOPHRENIA LIBRARY

Castillejos MC, Martín-Pérez C, Moreno-Küstner B

A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level

Psychological Medicine 2018; 48: 2101–15

[View review abstract online](#)

Comparison	Incidence of schizophrenia in males vs. females.
Summary of evidence	Moderate quality evidence (large sample, unable to assess consistency, imprecise, direct) suggests the incidence rate of schizophrenia or schizophreniform disorder is higher in men than in women.
Diagnosis of schizophrenia or schizophreniform disorder	
<i>A significant increased rate of schizophrenia or schizophreniform disorder in men; 4 population-based studies, IRR = 8.42, 95%CI 3.25 to 32.22, p < 0.01</i>	
Consistency in results	Unable to assess – heterogeneity measure is not reported.
Precision in results	Imprecise
Directness of results	Direct

Jongsma HE, Turner C, Kirkbride JB, Jones PB

International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis

The Lancet Public Health 2019; 4: e229-e44

[View review abstract online](#)

Comparison	Incidence of schizophrenia in males vs. females.
Summary of evidence	Moderate to high quality evidence (large samples, inconsistent, precise, direct) suggests the incidence rate of schizophrenia is

Sex differences

SCHIZOPHRENIA LIBRARY

	higher in men than in women.
Diagnosis of schizophrenia	
<i>A significant increased rate of schizophrenia or schizophreniform disorder in men; 11 studies (population and other designs), IRR = 1.70, 95%CI 1.46 to 1.97, p < 0.05, I² = 95%</i>	
Consistency in results	Inconsistent
Precision in results	Precise
Directness of results	Direct

van der Werf M, Hanssen M, Kohler S, Verkaaik M, Verhey FR, RISE Investigators, van Winkel R, van Os J, Allardyce J

Systematic review and collaborative recalculation of 133693 incident cases of schizophrenia

Psychological Medicine 2014; 44(1): 9-16

[Link to review abstract](#)

Comparison	Incidence of schizophrenia in males vs. females.
Summary of evidence	Moderate to high quality evidence (large samples, unable to assess consistency, precise, direct) suggests higher incidence of schizophrenia in males up until 39 years. Moderate quality evidence (imprecise) suggests no differences in incidence between 40 to 49 years, and higher incidence of schizophrenia in females over 50 years.
Diagnosis of schizophrenia	
<i>The risk of schizophrenia was significantly greater in men aged 20 to 39 years, and in women aged over 50 years, after adjusting for year of study, sample size, sampling frame (admission or contact), case ascertainment (clinical, systematic or interview) and diagnostic classification system. No differences were found between males and females aged 40 to 49 years;</i>	
33 samples (N = 63,550 incident cases of schizophrenia)	
< 20 years: IRR 0.53, 95%CI 0.41 to 0.69, p < 0.05	
20–29 years: IRR 0.47, 95%CI 0.41 to 0.54, p < 0.05	

Sex differences

SCHIZOPHRENIA LIBRARY

<p>30–39 years: IRR 0.80, 95%CI 0.71 to 0.91, $p < 0.05$ 40–49 years: IRR 1.18, 95%CI 0.99 to 1.41, $p > 0.05$ 50–59 years: IRR 1.50, 95%CI 1.25 to 1.80, $p < 0.05$ 60–69 years: IRR 1.50, 95%CI 1.13 to 1.99, $p < 0.05$ ≥ 70 years: IRR 1.38, 95%CI 0.93 to 2.05, $p > 0.05$</p>	
Consistency in results	No consistency measures are reported within age groups.
Precision in results	Precise for 20 to 39-year age groupings only.
Directness of results	Direct

Explanation of acronyms

CI = confidence interval, IRR = incidence rate ratio, N = number of participants, p = probability of obtaining that result ($p < 0.05$ generally regarded as significant), Q = test for heterogeneity, vs. = versus

Sex differences

Explanation of technical terms

* Bias has the potential to affect reviews of both RCT and observational studies. Forms of bias include; reporting bias – selective reporting of results, publication bias - trials that are not formally published tend to show less effect than published trials, further if there are statistically significant differences between groups in a trial, these trial results tend to get published before those of trials without significant differences; language bias – only including English language reports; funding bias - source of funding for the primary research with selective reporting of results within primary studies; outcome variable selection bias; database bias - including reports from some databases and not others; citation bias - preferential citation of authors. Trials can also be subject to bias when evaluators are not blind to treatment condition and selection bias of participants if trial samples are small⁶.

† Different effect measures are reported by different reviews.

Reliability and validity refers to how accurate the instrument is. Sensitivity is the proportion of actual positives that are correctly identified - 100% sensitivity = predict all people who are at high risk as developing psychosis and specificity is the proportion of negatives that are correctly identified - 100% specificity = not predicting anyone as being at high risk if they are truly not.

Weighted mean difference scores refer to mean differences between treatment and comparison groups after treatment (or occasionally pre to post treatment) and in a randomised trial there is an assumption that both groups are comparable on this measure prior to treatment. Standardized mean differences are divided by the pooled

standard deviation (or the standard deviation of one group when groups are homogenous) that allows results from different scales to be combined and compared. Each study's mean difference is then given a weighting depending on the size of the sample and the variability in the data. 0.2 represents a small effect, 0.5 a medium effect, and 0.8 and over represents a large effect⁶.

Odds ratio (OR) or relative risk (RR) refers to the probability of a reduction (< 1) or an increase (> 1) in a particular outcome in a treatment group, or a group exposed to a risk factor, relative to the comparison group. For example, a RR of 0.75 translates to a reduction in risk of an outcome of 25% relative to those not receiving the treatment or not exposed to the risk factor. Conversely, a RR of 1.25 translates to an increased risk of 25% relative to those not receiving treatment or not having been exposed to a risk factor. A RR or OR of 1.00 means there is no difference between groups. A medium effect is considered if $RR > 2$ or < 0.5 and a large effect if $RR > 5$ or < 0.2 ⁷. InOR stands for logarithmic OR where a InOR of 0 shows no difference between groups. Hazard ratios measure the effect of an explanatory variable on the hazard or risk of an event.

Correlation coefficients (eg, r) indicate the strength of association or relationship between variables. They are an indication of prediction, but do not confirm causality due to possible and often unforeseen confounding variables. An r of 0.10 represents a weak association, 0.25 a medium association and 0.40 and over represents a strong association. Unstandardised (b) regression coefficients indicate the average change in the dependent variable associated with a 1 unit change in the independent variable, statistically controlling for the other independent variables. Standardised regression coefficients represent the change

Sex differences

being in units of standard deviations to allow comparison across different scales.

‡ Inconsistency refers to differing estimates of treatment effect across trials (i.e. heterogeneity or variability in results) that is not explained by subgroup analyses and therefore reduces confidence in the effect estimate. I^2 is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) - 0% to 40%: heterogeneity might not be important, 30% to 60%: may represent moderate heterogeneity, 50% to 90%: may represent considerable heterogeneity and over this is considerable heterogeneity. I^2 can be calculated from Q (chi-square) for the test of heterogeneity with the following formula;

$$I^2 = \left(\frac{Q - df}{Q} \right) \times 100\%$$

§ Imprecision refers to wide confidence intervals indicating a lack of confidence in the effect estimate. Based on GRADE recommendations, a result for continuous data (standardised mean differences, not weighted mean differences) is considered imprecise if the upper or lower confidence limit crosses an effect size of 0.5 in either direction, and for binary and correlation data, an effect size of 0.25. GRADE also recommends downgrading the evidence when sample size is smaller than 300 (for binary data) and 400 (for continuous data), although for some topics, this criteria should be relaxed⁸.

|| Indirectness of comparison occurs when a comparison of intervention A versus B is not available but A was compared with C and B was compared with C that allows indirect comparisons of the magnitude of effect of A

versus B. Indirectness of population, comparator and or outcome can also occur when the available evidence regarding a particular population, intervention, comparator, or outcome is not available so is inferred from available evidence. These inferred treatment effect sizes are of lower quality than those gained from head-to-head comparisons of A and B.

Sex differences

References

1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009): Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *British Medical Journal* 151: 264-9.
2. GRADE Working Group (2004): Grading quality of evidence and strength of recommendations. *British Medical Journal* 328: 1490.
3. van der Werf M, Hanssen M, Kohler S, Verkaaik M, Verhey FR, Investigators R, *et al.* (2014): Systematic review and collaborative recalculation of 133,693 incident cases of schizophrenia. *Psychological medicine* 44: 9-16.
4. Castillejos MC, Martín-Pérez C, Moreno-Küstner B (2018): A systematic review and meta-analysis of the incidence of psychotic disorders: the distribution of rates and the influence of gender, urbanicity, immigration and socio-economic level. *Psychological Medicine* 48: 2101–15.
5. Jongsma HE, Turner C, Kirkbride JB, Jones PB (2019): International incidence of psychotic disorders, 2002-17: a systematic review and meta-analysis. *The Lancet Public Health* 4: e229-e44.
6. Cochrane Collaboration (2008): Cochrane Handbook for Systematic Reviews of Interventions. Accessed 24/06/2011.
7. Rosenthal JA (1996): Qualitative Descriptors of Strength of Association and Effect Size. *Journal of Social Service Research* 21: 37-59.
8. GRADEpro (2008): [Computer program]. Jan Brozek, Andrew Oxman, Holger Schünemann. *Version 3.2 for Windows*